Metraipolis › archive › dc_b528ebea2dc2
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome — Europe PMC PMID:41566667
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41566667
- DOI
- 10.1002/advs.202511449
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T15:13:19.784Z
- SHA-256 of the archived text
6805ea106c730d9edcc6f6366402f8958a5c4db70e22e1948df9e8a7a38a101f- Stable URL of this page
https://metraipolis.com/documento/dc_b528ebea2dc2
How to cite
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome — Europe PMC PMID:41566667 — Europe PMC (en), https://europepmc.org/article/MED/41566667 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b528ebea2dc2 (Metraipolis archive dc_b528ebea2dc2, sha256 6805ea106c730d9edcc6f6366402f8958a5c4db70e22e1948df9e8a7a38a101f)
BibTeX
@misc{dcb528ebea2dc2,
title = {Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome — Europe PMC PMID:41566667},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41566667},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b528ebea2dc2; sha256 6805ea106c730d9edcc6f6366402f8958a5c4db70e22e1948df9e8a7a38a101f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41566667. Agents can read the archived copy with the MCP tool read_document.